HER-2: Combination Therapy of a HER2-DC1 Dendritic Cell Cancer Vaccine and a Probiotic

FOR MORE INFORMATION ON THIS TECHNOLOGY, PLEASE CONTACT OUR OFFICE

Contact

The Innovation Office
813.745.6828
InnovationMarketing@Moffitt.org

20MA016N